Ultragenyx, Mereo Biopharma UX143 Orbit Study Final Analysis
Ultragenyx and Mereo BioPharma announced that the Phase 3 Orbit study of setrusumab for osteogenesis imperfecta (OI) in pediatric...
Tonix Publishes Phase 3 Fibromyalgia Trial Results of TNX-102 SL
Tonix Pharmaceuticals announced positive Phase 3 RESILIENT trial results for TNX-102 SL (sublingual cyclobenzaprine HCl tablets) in managing fibromyalgia...
Sil204 Shows Efficacy in Human Lung Cancer Cell Lines
Silexion Therapeutics (NASDAQ: SLXN) announced positive preclinical data for SIL204, its RNA interference (RNAi) therapy, in human lung cancer...
Seclidemstat’s Role in LSD1 Inhibition Validated in Oncology Studies
Salarius Pharmaceuticals announced positive preclinical data on its LSD1 inhibitor, seclidemstat, and provided an update on its merger with...
BioVie’s Bezisterim Shows Potential to Slow or Reverse Aging
BioVie Inc. presented data from its Phase 3 NM101 study on bezisterim, a drug candidate for Alzheimer’s diseaseAlzheimer’s disease,...
Fifty1 Labs Redefines Long COVID Treatment with AI
Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has successfully completed its REVIVE Adaptive Platform...
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Cognition Therapeutics met with the FDA to discuss Phase 2 trial results for their Alzheimer’s drug, zervimesine (CT1812), and...
PDS0101 Met Criteria for Expansion to Phase 2 Trial Following Positive Results
PDS Biotechnology Corporation announced positive results from Stage 1 of a National Cancer Institute (NCI)-led clinical trial for PDS01ADC,...
How GSK & AstraZeneca Drove Change With Veeva Site Connect
The 2025 Veeva R&D and Quality Summit showcased the transformative potential of Veeva Site Connect in clinical trials, with...
Artelo Biosciences: Positive Preclinical Efficacy of ART12.11 in Stress-Induced Depression
Artelo Biosciences announced preclinical data for its CBD-TMP cocrystal drug, ART12.11, at the International Cannabinoid Research Society Symposium. The...